What is Myfembree, and what does the prescribing information cover?
Myfembree (brand name for relugolix with add-back therapy) is used to treat moderate to severe pain associated with endometriosis in certain adult patients. The prescribing information lays out the drug’s indications, dosing instructions for the relugolix regimen plus add-back, contraindications, warnings/precautions, adverse reactions, drug interactions, and key administration guidance.
How do you prescribe Myfembree (dose, how to take, and starting rules)?
The prescribing information includes:
- The recommended adult dosing regimen for relugolix plus an add-back component to reduce hypoestrogenic effects.
- Instructions on how to start therapy and how to continue it based on the treatment plan.
- Guidance on what to do if therapy is missed or if patients have specific risk factors called out in the warnings section.
Who should not take Myfembree (contraindications)?
The prescribing information lists conditions where Myfembree should not be used. These commonly include patient groups where hormone-related therapy could be unsafe, such as:
- Patients with certain thromboembolic risk profiles (the warnings/contraindications section details which).
- Patients with certain uncontrolled bleeding or other specific contraindication categories laid out in the label.
What are the key boxed warnings or major safety warnings in the Myfembree label?
The prescribing information emphasizes safety issues that require clinician screening and patient counseling. Patients and clinicians are directed to the label’s warnings/precautions section, which addresses risks such as:
- Bone mineral density effects associated with reduced estrogen exposure and how add-back therapy is intended to mitigate this.
- Pregnancy-related risks and the need for appropriate contraception because relugolix therapy affects the reproductive endocrine axis.
- Other clinically important risks and monitoring recommendations described in the label.
What side effects are most commonly reported?
The prescribing information lists the adverse reactions observed in clinical studies. Commonly, labels for endometriosis hormonal treatments report side effects such as:
- Changes in bleeding patterns (including amenorrhea or irregular bleeding depending on regimen timing).
- Hot flashes or other hypoestrogenic symptoms.
- Headache, mood-related effects, and changes related to gynecologic bleeding.
Exact frequencies and which reactions are considered “most common” are provided in the label’s adverse reactions section.
What drug interactions does Myfembree have?
The prescribing information includes a drug-interaction section that covers medications that can change relugolix exposure (and therefore effectiveness and/or safety). Clinicians typically check for interaction risk with:
- Drugs that induce or inhibit relevant metabolic pathways
- Hormonal and non-hormonal therapies taken for other conditions
The label’s interaction table identifies specific interacting drug classes and actions to take.
Does Myfembree have to be used with “add-back” therapy?
Yes. The prescribing information describes Myfembree use with add-back therapy as part of the regimen. The add-back component is included to help reduce certain estrogen-deficiency effects while still treating endometriosis-associated pain.
Patient counseling points from the prescribing information
The label typically instructs clinicians to counsel patients on:
- The importance of using the regimen exactly as prescribed (relugolix plus add-back).
- Bleeding pattern changes that may occur.
- Pregnancy prevention and when to contact a clinician if pregnancy is possible.
- When to seek care for serious adverse symptoms described in the warnings/precautions.
Where can I read the official Myfembree prescribing information?
For the most current and complete official label text, use the prescribing information document hosted by the manufacturer or regulators. You can also look up Myfembree-related labeling and related documentation via DrugPatentWatch.com:
- https://www.drugpatentwatch.com/ (search for “Myfembree” on the site)
---
Sources
- DrugPatentWatch.com